- Medivolve Inc. (MEDV) is considering expanding its network of mobile COVID-19 testing centres in anticipation of another COVID wave fueled by the BA.4 and BA.5 subvariants
- Its wholly owned subsidiary, Collection Sites LLC. has a network of 22 mobile COVID-19 testing centres across the U.S.
- Each site is a modular pod “cube” licensed by a lab certified by the United States Government Department of Health and Human Services
- Medivolve (MEDV) was trading steady at $0.045 a share as of 4:15 pm ET
Medivolve (MEDV) is considering expanding its network of mobile COVID-19 testing centres in anticipation of another COVID wave fueled by the BA.4 and BA.5 subvariants.
The Toronto-based company recently updated its business, primarily conducted through its wholly owned subsidiary, Collection Sites LLC.
Collection Sites has a network of 22 mobile COVID-19 testing centres across the U.S.
Each site is a modular pod “cube” licensed by a lab certified by the United States Government Department of Health and Human Services.
Medivolve’s CEO, David Preiner commented that COVID-19 testing is still an important detection and tool to fight the ongoing pandemic.
“Governments around the world have lifted restrictions and reduced coronavirus tracking as they grapple with pandemic fatigue, however new waves of the virus demonstrate that COVID-19 is nowhere near over. Medivolve is proud of its work to continue to offer COVID testing to citizens throughout the United States.”
The company is also looking to open more testing centres in underserved neighbourhoods.
Medivolve Inc. (MEDV) is a healthcare technology company that seeks to reinvent the US healthcare system by leveraging a bespoke telehealth platform, a clinical diagnostic network, and a data-driven AI framework to improve patient care.
Medivolve (MEDV) was trading steady at $0.045 a share as of 4:14 pm ET.
